Advertisement

Clinical Drug Investigation

, Volume 18, Issue 3, pp 183–188 | Cite as

Analysis of Clarithromycin and Propicillin in the Management of Streptococcal Pharyngotonsillitis in Children

  • Nicolás Padilla
  • Roberto Figueroa
  • Mario Muñoz
Clinical Use
  • 19 Downloads

Abstract

Objective: To compare the clinical and bacteriological efficacy and safety of clarithromycin and propicillin in the treatment of streptococcal pharyngotonsillitis in children.

Design: This was a prospective, non-blind, longitudinal, comparative study. All patients included were randomised to receive either clarithromycin or propicillin.

Setting: Participants were outpatients attending a private paediatric clinic in Celaya, Guanajuato, Mexico.

Patients: Patients aged between 1 and 15 years presenting with signs and symptoms of pharyngotonsillitis were enrolled in this study.

Interventions and Outcome Measures: The dosage of clarithromycin was 15 mg/kg/day divided into two daily doses, and for propicillin it was 25 000 U/kg/day divided into three daily doses. Both drugs were given for 10 days. Patients were evaluated according to resolution of signs and symptoms, and adverse events. Pharyngeal cultures were collected at the initial office visits and 3 days after the conclusion of drug therapy. Data were analysed using the Epi5 computer program and χ2 tests were performed regarding time to resolution of clinical signs, adverse events and bacteriological cure.

Results: Of the 387 patients presenting with signs of pharyngotonsillitis, 189 were culture positive. A total of 102 were randomised to receive clarithromycin and 87 to receive propicillin. A statistically significant difference in resolution of clinical signs at 48 hours after initiation of treatment was found in favour of clarithromycin for dysphagia (χ2 = 59.21; p < 0.00001), pharyngeal erythema (χ2 = 61.48; p < 0.00001) and pharyngeal exudate (χ2 = 103.61; p < 0.00001). Statistically significant differences in favour of clarithromycin were also seen on days 5, 7 and 9 of treatment for all these signs. Bacteriological efficacy tended to be higher with clarithromycin [relative rate for bacteriological success with clarithromycin = 1.11; confidence interval = 1.00 to 1.24;χ2 (Yates) = 3.05; p = 0.08]; these differences were not significant. 11 patients would need to be treated with clarithromycin to yield bacteriological success in 1 additional patient. Clarithromycin showed a lower overall rate of adverse events, but abdominal pain and nausea were more common with this agent.

Conclusions: Clarithromycin is an excellent alternative in the treatment of streptococcal pharyngotonsillitis in children because of its higher clinical (95% vs 86% of propicillin) and bacteriological (92% vs 82% of propicillin) efficacy and the faster rate of improvement than with propicillin.

Keywords

Adis International Limited Clarithromycin Rheumatic Fever Tonsillitis Clin Drug Invest 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Serafín F. Infecciones agudas de las vías respiratorias superiores. In: Levy S, editor. Otorrinolaringología pediátrica. Mexico City, Interamericana, 1985: 87–95Google Scholar
  2. 2.
    Vega L. Terapeútica antimicrobiana en infecciones estreptocóccicas. Rev Mex Pediatr 1993; 60: 2–4Google Scholar
  3. 3.
    Tristan J, Lopez H. Rhinitis, sinusitis and pharyngotonsillitis [in Spanish]. Rev Mex Pediatr 1990; 57: 19–26Google Scholar
  4. 4.
    Kumate J. Infecciones de vías respiratorias superiores. In: Kumate J, Gutiérrez G, Muñoz O, et al, editors. Manual de infectología. Mexico City, Francisco Mendez Cervantes, 1990: 147–57Google Scholar
  5. 5.
    Auhagen E, Gloxhuber C, Hecht G, et al. Propicillin (Baycillin). Arzneimittelforschung 1992; 12: 751–70Google Scholar
  6. 6.
    Koch H, Brüning Y, Manoharan M, et al. Wolf Mit vollem Magen geht es auch Ärstl. Praxis 1986; 80: 2495–7Google Scholar
  7. 7.
    American Academy of Pediatrics. 1994 Red Book: Report of the Committee on Infectious Diseases. Group A streptococcal infections. 23rd ed. Elk Grove Village, IL: American Academy of Pediatrics, 1994: 430–9Google Scholar
  8. 8.
    Rodriguez R, editor. Diagnóstico y tratamiento de la faringoamigdalitis estreptococcica aguda. Infecciones de vías respiratorias superiores en pediatria. Mexico City, Dr. Romeo S. Rodríguez 1989; 1–61Google Scholar
  9. 9.
    Rodriguez R, Mendez J, Espinoza L, et al. The usefulness of the benzatinic penicillin combining in the treatment of the streptococcal pharyngotonsillitis [in Spanish]. Bol Med Hosp Infant Mex 1988; 45: 797–802PubMedGoogle Scholar
  10. 10.
    Padilla N, Figueroa RC, Rivera MR, at al. Comparative study of the treatment of streptococcal pharyngotonsillitis with clarithromycin and amoxicillin/clavulanate [in Spanish]. Rev Mex Pediatr 1995; 62: 13–5Google Scholar
  11. 11.
    Padilla N. Comparison of clarithromycin and azithromycin for treatment of streptococcal pharyngotonsillitis in children. Infect Med 1998; 15Suppl. 1: 23–7Google Scholar
  12. 12.
    Zuckerman JM, Kaye KM. The newer macrolides; azithromycin and clarithromycin. Infect Dis Clin North Am 1995; 9(3): 731–45PubMedGoogle Scholar
  13. 13.
    Breese BA. Simple scorecard for the tentative diagnosis of streptococcal pharyngitis. Am J Dis Child 1977; 131: 514–7PubMedGoogle Scholar
  14. 14.
    Padilla N, Figueroa RC, Muñoz M. Breese’s score in the clinical diagnosis of streptococcal pharyngotonsillitis [in Spanish]. Rev Mex Pediatr 1997; 64: 96–8Google Scholar
  15. 15.
    Faklam RR. Isolation and identification of streptococci. III. Presumptive identification of streptococci by nonserological methods. Staphylococcus and Streptococcus Section. Atlanta (GA): Centers for Disease Control, 1980Google Scholar
  16. 16.
    Cammann U, Stille W. Erfahrungen mit propicillin bei angina tonsillaris in der kinderárztlichen. Praxis Der Kinderarzt 1987; 3: 377–8Google Scholar
  17. 17.
    Guay DR. Macrolide antibiotics in paediatric infectious disease. Drugs 1996; 51(4): 515–36PubMedCrossRefGoogle Scholar
  18. 18.
    Tarlow M. Macrolides in the management of streptococcal pharyngitis/tonsillitis. Pediatr Infect Dis J 1997; 16(4): 444–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • Nicolás Padilla
    • 1
  • Roberto Figueroa
    • 1
  • Mario Muñoz
    • 2
  1. 1.Research Unit, Nursing and Obstetrics School of CelayaUniversity of GuanajuatoCelaya, GtoMexico
  2. 2.Clinical Laboratory ‘JR’CelayaMexico

Personalised recommendations